Objective: The REONPARK study aims to evaluate COMT inhibitor (iCOMT) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s Disease patients with early motor fluctuations (EMF, signs of wearing-off within ≤2 years) in real-world clinical practice.
Background: In PD, iCOMT usage extends L-dopa bioavailability and may lead to a more continuous delivery to the brain [1]. Available iCOMT include opicapone, entacapone and tolcapone. Evidence indicates comparable iCOMT efficacy in reducing off-time and increasing on-time in both patients with recent and long-standing motor fluctuations, but with less incidence of dyskinesias in recent cases [2].
Method: The REONPARK is a national observational iCOMT study enrolling PD patients treated with L-dopa/DDCI and EMF. Presented here is the first interim analysis, comparing 3-months post iCOMT initiation to baseline.
Results: 70 evaluable patients (mean±SD: 64.4±10 years old; 4.8±3.1 years PD duration; 484.8±212 mg/day L-dopa, MDS-UPDRS III: 28.7±15) initiated opicapone, with 75% on 3 L-dopa intakes. After 3-months, motor symptoms were reduced without increasing dyskinesias (Table 1). Condition was improved in most patients according to Patient and Clinical Global Impression of Change (62.9% and 73.5%, respectively). Mood/cognition domain in the NMSS also improved (mean±SD: -2.7±9.3, p<0.006). Sixty-six patients completed the follow-up, 2 discontinued due to adverse events. Eighteen opicapone-related adverse events were reported, all mild or moderate, affecting 18.60% of the patients.
Conclusion: Opicapone demonstrated effective control of motor symptoms and good tolerability in PD patients with EMF in routine clinical practice after 3 months.
Table 1.-
References: 1. Eur Neurol. 2010;63(5):257-66.
2. Mov Disord. 2020;35(suppl 1):444.
To cite this abstract in AMA style:
L. Lopez Manzanares, J. Garcia Caldentey, R. Garcia-Ramos, M. Cerdan Sanchez, B. Solano Vila, G. Castilla-Fernandez, I. Pijuan Jimenez, I. Tegel Ayuela. Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study. [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/opicapone-real-world-experience-in-early-motor-fluctuations-3-months-analysis-of-the-reonpark-study/. Accessed November 23, 2024.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/opicapone-real-world-experience-in-early-motor-fluctuations-3-months-analysis-of-the-reonpark-study/